On the second day of the American Society of Clinical Oncology (ASCO) conference, BioNTech and Pfizer presented what the firms described as promising data on their bispecific antibody therapies targeting lung cancer. The results add to a growing wave of new immunotherapies that have captured attention at this year's meeting.
The data arrives as the oncology space faces intense competition, with multiple drugmakers vying for breakthroughs in lung cancer — a disease that causes more than a million deaths annually. Rick Pazdur, the FDA's top oncology official, used the occasion to offer characteristically direct remarks, seeing a silver lining in the agency's engagement with novel therapies.
Neither BioNTech nor Pfizer disclosed specific numerical outcomes in the source material, but the treatments belong to a class known as bispecifics — engineered antibodies that bind to two different targets simultaneously. Such agents have shown particular promise in overcoming tumor resistance to conventional immunotherapies.
Investor and physician interest will likely center on how these bispecifics compare to existing checkpoint inhibitors, which have revolutionized treatment but fail in a substantial subset of patients. The data suggest these newer modalities could eventually expand the pool of patients who benefit from immunotherapy.
Pazdur's comments underscored the FDA's evolving stance — balancing accelerated approvals against the need for robust confirmatory trials. His perspective carries weight as regulators and developers navigate that tension.